/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

AbCellera Biologics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.52 0.0087(0.87%) ABCL at 04 Dec 2025 04:24 PM Biotechnology
Lowest Today 3.44
Highest Today 3.56
Today’s Open 3.46
Prev. Close 3.46
52 Week High 6.52
52 Week Low 1.89
Day’s Range: Low 3.44 High 3.56
52-Week Range: Low 1.89 High 6.52
1 day return -
1 Week return -6.55
1 month return -28.16
3 month return -16.08
6 month return +44.42
1 year return +20.93
3 year return -70.63
5 year return -94.02
10 year return -

Institutional Holdings

Baker Bros Advisors LP 9.21

American Funds SMALLCAP World A 4.47

Capital World Investors 4.47

Baillie Gifford & Co Limited. 3.47

UBS Asset Mgmt Americas Inc 2.83

SMDS Global AI Equity Mother 1.50

Two Sigma Investments LLC 1.38

ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 1.37

Two Sigma Advisers, LLC 1.36

Baillie Gifford Positive Change 1.30

Baillie Gifford Positive Change B Acc 1.30

BlackRock Inc 1.23

UBS Group AG 1.15

UBS Lux Dgtl Hlth Eq Fd seeding P acc 1.14

Millennium Management LLC 1.14

Orbimed Advisors, LLC 1.12

Renaissance Technologies Corp 1.11

Citadel Advisors Llc 0.97

TANG CAPITAL MANAGEMENT LLC 0.87

Baillie Gifford WW Pstv Chg B USD Acc 0.76

ACATIS Datini Valueflex Fonds A 0.62

Guardian Partners Inc. 0.60

iShares Biotechnology ETF 0.45

Morgan Stanley - Brokerage Accounts 0.33

Novo A/S 0.22

NORGES BANK 0.21

State Street Corp 0.21

Susquehanna International Group, LLP 0.20

iShares Genomics Immnlgy & Hlthcr ETF 0.19

SPDR® Portfolio Developed Wld ex-US ETF 0.17

Lazard Digital Health 0.16

Baillie Gifford Positive Chg CI FD Cl E 0.15

Keystone Positive Change Investment Ord 0.14

Vanguard Baillie GiffordGlbPstvImpStkInv 0.13

Desjardins Sustainable Positive Change F 0.13

BlackRock Advantage Small Cap Core Instl 0.12

SEB Artificial Intelligence D (USD) 0.11

iShares Healthcare Innov ETF USD Acc 0.09

Fidelity Nasdaq Composite ETF 0.08

DNB Fund - Disruptive Opp Retail A EUR 0.07

Market Status

Strong Buy: 6

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1035.70 M

PB Ratio 1.0728

PE Ratio 0.0

Enterprise Value 680.75 M

Total Assets 1360.55 M

Volume 3362198

Company Financials

Annual Revenue FY23:50391000 50.4M, FY22:485424000 485.4M, FY21:11611543 11.6M, FY20:233155000 233.2M, FY19:11611543 11.6M

Annual Profit FY23:48837000 48.8M, FY22:418988000 419.0M, FY21:11611543 11.6M, FY20:206012000 206.0M, FY19:11611543 11.6M

Annual Net worth FY23:-129141000 -129.1M, FY22:158519000 158.5M, FY21:-2210696 -2.2M, FY20:118918000 118.9M, FY19:-2419892 -2.4M

Quarterly Revenue Q3/2025:8955000 9.0M, Q2/2025:17084000 17.1M, Q1/2025:4235000 4.2M, Q3/2024:6507000 6.5M, Q2/2024:7323000 7.3M

Quarterly Profit Q3/2025:8955000 9.0M, Q2/2025:10025000 10.0M, Q1/2025:4235000 4.2M, Q3/2024:-31788000 -31.8M, Q2/2024:-30714000 -30.7M

Quarterly Net worth Q3/2025:-57119000 -57.1M, Q2/2025:-34727000 -34.7M, Q1/2025:-45621000 -45.6M, Q3/2024:-51107000 -51.1M, Q2/2024:-36930000 -36.9M

Fund house & investment objective

Company Information AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Organisation Biotechnology

Employees 596

Industry Biotechnology

CEO Dr. Carl L.G. Hansen Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow